TLDR
- Shares of Centene tumbled 14% Tuesday, ranking as the S&P 500’s biggest loser for the session
- ACA marketplace membership projected to fall to 3.5 million by Q1’s close, down from 5.5 million in December
- Management confirmed adjusted EPS outlook exceeding $3 for 2026
- Mizuho downgraded price target from $47 to $41 while keeping Neutral stance
- Medicare Advantage segment continues operating in the red, with profitability not expected until 2026 ends
Investors holding Centene shares have endured a challenging year, and Tuesday’s session only compounded their pain. The healthcare insurance provider saw its shares crater 14% following CEO Sarah London’s presentation at the Barclays Global Healthcare Conference, where her disclosure about membership attrition sent shockwaves through the market.
During her conference appearance, London assured participants that the company’s three primary business segments are performing according to expectations for 2026. She confirmed the adjusted earnings forecast of over $3 per share — precisely aligned with the $3 consensus projection from FactSet analysts.
However, there was little cause for optimism. The unchanged guidance provided no positive surprise, and market participants fixated on the deteriorating membership numbers.
Management now projects ACA marketplace enrollment will conclude Q1 at 3.5 million members, representing a sharp decline from December’s 5.5 million. February figures showed enrollment at 3.6 million.
London indicated Centene had forecasted the overall market would contract “somewhere between the high teens and the mid-thirties” on a percentage basis. She noted the company anticipated landing “at the higher end of that and possibly higher than the top end of that.”
She explained that strategic pricing adjustments implemented early in the year contributed to the membership decline, as Centene chose to emphasize profitability enhancement over expanding its member base.
Medicare Advantage Still a Drag
The Medicare Advantage division remains a persistent headwind for Centene’s performance. This segment operated at a loss throughout 2025 and is projected to stay marginally unprofitable during 2026, with management targeting breakeven performance by 2027.
Another cloud looming over the stock involves the final rate determination from the Centers for Medicare and Medicaid Services, scheduled for release no later than April 6. The Trump administration’s earlier proposal to maintain Medicare rates essentially flat for 2027 negatively impacted Centene and its industry competitors.
London mentioned the company provided feedback to CMS regarding the Advance Rate Notice and voiced optimism that final rates would more accurately account for current medical cost patterns affecting the sector.
Analyst Reaction
Mizuho responded swiftly following the conference presentation. The research firm reduced its price objective on Centene to $41 from $47 while maintaining its Neutral recommendation.
Mizuho highlighted worries surrounding health insurance exchange member departures and specialty pharmaceutical cost pressures. The firm indicated it is implementing a more cautious valuation framework pending additional transparency on the extent of enrollment deterioration.
Truist Securities adopted a more constructive perspective, preserving its Buy recommendation with a $49 price objective, pointing to margin expansion potential and executive team conviction. Cantor Fitzgerald remained at Neutral with a $41 target, characterizing the 2026 operating landscape as difficult.
For perspective, Centene has declined 9.7% during 2026, compared to a 0.7% retreat for the S&P 500.
The shares have nevertheless outperformed certain competitors. Molina Healthcare has dropped 17% year-to-date, Elevance Health is down 18%, and UnitedHealth Group has fallen 14%.
Centene’s Q4 2025 financial results revealed an adjusted diluted loss per share of $1.19, narrowly surpassing the anticipated $1.22 loss. Revenue reached $49.73 billion, exceeding the $48.39 billion consensus estimate.
InvestingPro estimates Centene’s intrinsic value at $62.11, with Wall Street analysts forecasting EPS of $3.05 for the complete 2026 fiscal year.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
